Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-4208 700 μg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg |
| Sequence 2 | EXPERIMENTAL | Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg |
| Sequence 3 | EXPERIMENTAL | Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg |
| Sequence 4 | EXPERIMENTAL | Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | - |
| TD-4208 700 μg | DRUG | - |
| TD-4208 350 μg | DRUG | - |
| Ipratropium 500 μg | DRUG | - |
Inclusion Criteria: * Diagnosis of moderate stable Chronic Obstructive Pulmonary. * Disease with FEV1/FVC \<0.7 at screening. * Woman of non-childbearing potential. * Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth ...
TD-4208 700 μg is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
TD-4208 700 μg is being developed by Viatris Inc., a pharmaceutical company traded on the NASDAQ under the ticker symbol VTRS. The drug is in Phase 2 clinical development for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
TD-4208 700 μg is in Phase 2 clinical development. It is an investigational drug for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and has not yet been approved by regulatory authorities.
TD-4208 700 μg has one completed Phase 2 clinical trial, identified as NCT03064113, titled 'Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)'. The trial enrolled 32 participants in New Zealand and was randomized, double-blind, and controlled.
TD-4208 700 μg is a specific dose of the drug TD-4208, which is being developed by Viatris Inc. for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The 700 μg dose was studied in a Phase 2 clinical trial.